Price$2.10-0.03 (-1.41%)
01:30 PM07:45 PM
News · 26 weeks38-50%
2025-12-072026-05-31
Mix1790d
- Other8(47%)
- Insider7(41%)
- SEC Filings1(6%)
- Earnings1(6%)
Latest news
25 items- PRAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t
- PRAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic PreparednessSAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology. According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of
- INSIDERSEC Form 4 filed by Gikakis Nicolas4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Broenniman Edward G4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Rossetti Angela4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Shah Chetan4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Shah Chetan4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Gikakis Nicolas4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Broenniman Edward G4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- PRPresenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live streamMIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a
- PRPresenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live streamMIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to
- PRAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB ReviewSAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure". The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors
- SECSEC Form 8-K filed by Aethlon Medical Inc.8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- PRAethlon Medical Engages Maxim Group LLC to Evaluate Strategic OpportunitiesSAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Co
- PRLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
- PRAethlon Medical to Present at the Life Sciences Investor Forum on March 12thSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, CEO and CFO, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. DATE: Thursday, March 12thTIME: 1:00 – 1:30 pm ET REGISTER HERE Available for 1x1 meetings: March 12th. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportun
- PRPresenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live streamMIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi
- PRPresenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live streamMIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayFebruary 25, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go
- SECAethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical to Present on the Emerging Growth Conference on February 25th 2026Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in
- SECSEC Form 10-Q filed by Aethlon Medical Inc.10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate UpdateClinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr
- PRAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034
AEMD FAQ
6 questionsWhat does Aethlon Medical Inc. do?
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for...Where does AEMD stock trade?
Aethlon Medical Inc. (AEMD) is listed on NASDAQ.What sector and industry is AEMD in?
Aethlon Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AEMD?
Aethlon Medical Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $150.00 price target on 2025-07-07.What companies are similar to AEMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AEMD side-by-side with any of them on Quantisnow.How can I track AEMD on Quantisnow?
Quantisnow aggregates Aethlon Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEMD to receive live email and push alerts on every new disclosure.